Cargando…

Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis

Objective: Chronic nonatrophic gastritis (CNG) is the most common digestive disease. In China, Zuojin pill (ZJP) is considered an effective medicine formula for CNG. However, its efficacy and mechanism have never been explored. In order to understand how and why ZJP demonstrates therapeutic effect o...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Xiao, Xie, Shuying, Wang, Ruilin, Wang, Zhongxia, Jing, Manyi, Li, Haotian, Wei, Shizhang, Liu, Honghong, Li, Jianyu, He, Qingyong, Zhao, Yanling
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310101/
https://www.ncbi.nlm.nih.gov/pubmed/35899115
http://dx.doi.org/10.3389/fphar.2022.898680
_version_ 1784753316363763712
author Ma, Xiao
Xie, Shuying
Wang, Ruilin
Wang, Zhongxia
Jing, Manyi
Li, Haotian
Wei, Shizhang
Liu, Honghong
Li, Jianyu
He, Qingyong
Zhao, Yanling
author_facet Ma, Xiao
Xie, Shuying
Wang, Ruilin
Wang, Zhongxia
Jing, Manyi
Li, Haotian
Wei, Shizhang
Liu, Honghong
Li, Jianyu
He, Qingyong
Zhao, Yanling
author_sort Ma, Xiao
collection PubMed
description Objective: Chronic nonatrophic gastritis (CNG) is the most common digestive disease. In China, Zuojin pill (ZJP) is considered an effective medicine formula for CNG. However, its efficacy and mechanism have never been explored. In order to understand how and why ZJP demonstrates therapeutic effect on CNG, a clinical trial was conducted. Metabolomics was used to explore its deep mechanism. Methods: A total of 14 patients with CNG were recruited from October 2020 to March 2021 (ChiCTR2000040549). The endoscopy and histopathological changes were evaluated as efficacy. Serum samples were prepared and detected by performing widely targeted metabolome using UPLC. Multivariate statistical analysis was conducted to identify potential differential metabolites and signaling pathways. Last, the signal-related inflammatory factors containing COX-2, IL-4, and IL-17 were confirmed via immunohistochemical staining and enzyme-linked immunosorbent assay. Results: ZJP was able to alleviate several indexes of mucosal injury under endoscopy and histology. Erosion and bile reflux, but not red plaques and hemorrhage, were downregulated by ZJP. In addition, it could remarkably alleviate active chronic inflammation. A total of 14 potential metabolites, namely, hypoxanthine, adipic acid, D-ribono-1,4-lactone, L-sepiapterin, imidazoleacetic acid, sebacate, ADP-ribose, 4-hydroxybenzyl alcohol, 11,12-EET, 15-OxoETE, 12-OxoETE, (±)8-HETE, glycyrrhizinate, and DL-aminopimelic acid, were discriminated by metabolomics. Moreover, certain amino acid metabolism got significance during the disease progress and treatment. The related inflammatory factors including COX-2, IL-4, and IL-17 were inhibited by ZJP in both mucosa and serum. Conclusion: All these results indicated that ZJP partially acts as an inflammatory suppressor to regulate comprehensive metabolism disorders. This might be an important mechanism of ZJP in the treatment of CNG.
format Online
Article
Text
id pubmed-9310101
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-93101012022-07-26 Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis Ma, Xiao Xie, Shuying Wang, Ruilin Wang, Zhongxia Jing, Manyi Li, Haotian Wei, Shizhang Liu, Honghong Li, Jianyu He, Qingyong Zhao, Yanling Front Pharmacol Pharmacology Objective: Chronic nonatrophic gastritis (CNG) is the most common digestive disease. In China, Zuojin pill (ZJP) is considered an effective medicine formula for CNG. However, its efficacy and mechanism have never been explored. In order to understand how and why ZJP demonstrates therapeutic effect on CNG, a clinical trial was conducted. Metabolomics was used to explore its deep mechanism. Methods: A total of 14 patients with CNG were recruited from October 2020 to March 2021 (ChiCTR2000040549). The endoscopy and histopathological changes were evaluated as efficacy. Serum samples were prepared and detected by performing widely targeted metabolome using UPLC. Multivariate statistical analysis was conducted to identify potential differential metabolites and signaling pathways. Last, the signal-related inflammatory factors containing COX-2, IL-4, and IL-17 were confirmed via immunohistochemical staining and enzyme-linked immunosorbent assay. Results: ZJP was able to alleviate several indexes of mucosal injury under endoscopy and histology. Erosion and bile reflux, but not red plaques and hemorrhage, were downregulated by ZJP. In addition, it could remarkably alleviate active chronic inflammation. A total of 14 potential metabolites, namely, hypoxanthine, adipic acid, D-ribono-1,4-lactone, L-sepiapterin, imidazoleacetic acid, sebacate, ADP-ribose, 4-hydroxybenzyl alcohol, 11,12-EET, 15-OxoETE, 12-OxoETE, (±)8-HETE, glycyrrhizinate, and DL-aminopimelic acid, were discriminated by metabolomics. Moreover, certain amino acid metabolism got significance during the disease progress and treatment. The related inflammatory factors including COX-2, IL-4, and IL-17 were inhibited by ZJP in both mucosa and serum. Conclusion: All these results indicated that ZJP partially acts as an inflammatory suppressor to regulate comprehensive metabolism disorders. This might be an important mechanism of ZJP in the treatment of CNG. Frontiers Media S.A. 2022-07-11 /pmc/articles/PMC9310101/ /pubmed/35899115 http://dx.doi.org/10.3389/fphar.2022.898680 Text en Copyright © 2022 Ma, Xie, Wang, Wang, Jing, Li, Wei, Liu, Li, He and Zhao. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Ma, Xiao
Xie, Shuying
Wang, Ruilin
Wang, Zhongxia
Jing, Manyi
Li, Haotian
Wei, Shizhang
Liu, Honghong
Li, Jianyu
He, Qingyong
Zhao, Yanling
Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
title Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
title_full Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
title_fullStr Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
title_full_unstemmed Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
title_short Metabolomics Profiles Associated with the Treatment of Zuojin Pill on Patients with Chronic Nonatrophic Gastritis
title_sort metabolomics profiles associated with the treatment of zuojin pill on patients with chronic nonatrophic gastritis
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310101/
https://www.ncbi.nlm.nih.gov/pubmed/35899115
http://dx.doi.org/10.3389/fphar.2022.898680
work_keys_str_mv AT maxiao metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT xieshuying metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT wangruilin metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT wangzhongxia metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT jingmanyi metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT lihaotian metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT weishizhang metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT liuhonghong metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT lijianyu metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT heqingyong metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis
AT zhaoyanling metabolomicsprofilesassociatedwiththetreatmentofzuojinpillonpatientswithchronicnonatrophicgastritis